✦ LIBER ✦

Phase II Study of Trabectedin in Pretreated Patients with Advanced Colorectal Cancer

✍ Scribed by Luis Paz-Ares; Fernando Rivera-Herreros; Eduardo Díaz-Rubio; Margarita García; Esther Casado; Ricardo Cubedo; Cristina Gravalos; Vicente Alfaro; Javier Gómez; Miguel Angel Izquierdo; Josep Tabernero

Book ID: 119935093
Publisher: CIG Media Group, LP.
Year: 2007
Tongue: English
Weight: 139 KB
Volume: 6
Category: Article
ISSN: 1533-0028
DOI: 10.3816/ccc.2007.n.018

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase II study of tallysomycin S10b in p

Phase II study of tallysomycin S10b in patients with advanced colorectal cancer

✍ C. Nicaise; J. Ajani; P. Goudeau; M. Rozencweig; B. Levin; I. Krakoff 📂 Article 📅 1990 🏛 Springer 🌐 English ⚖ 201 KB

Carboplatin in patients with advanced co

Carboplatin in patients with advanced colorectal cancer pretreated with fluoropyrimidines

✍ Nolè, F.; Biganzoli, L.; Buzzoni, R.; Bajetta, E. 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 245 KB

Suramin in patients with metastatic colo

Suramin in patients with metastatic colorectal cancer pretreated with fluoropyrimidine-based chemotherapy. A phase II Study

✍ Alfredo Falcone; Elisabetta Pfanner; Claudia Cianci; Romano Danesi; Isa Brunetti 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 358 KB 👁 2 views

Vinorelbine-induced neurotoxicity in pat

Vinorelbine-induced neurotoxicity in patients with advanced breast cancer pretreated with paclitaxel – a phase II study

✍ B. Fazeny; U. Zifko; Siegfried Meryn; Heinz Huber; Wolfgang Grisold; Christian D 📂 Article 📅 1996 🏛 Springer 🌐 English ⚖ 135 KB

Phase II study of pyrazoloacridine in pa

Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma

✍ Mark M. Zalupski; Philip A. Philip; Patricia LoRusso; Anthony F. Shields 📂 Article 📅 1997 🏛 Springer 🌐 English ⚖ 101 KB

Phase II study of spirogermanium in pati

Phase II study of spirogermanium in patients with advanced colorectal carcinoma

✍ Jaffer A. Ajani; Jack S. Faintuch; Roxann K. McClure; Bernard Levin; Bruce M. Bo 📂 Article 📅 1986 🏛 Springer US 🌐 English ⚖ 193 KB

Twenty one evaluable patients with advanced colorectal carcinoma were treated with continuous infusion of spirogermanium at a median daily dose of 150 mg/rn 2 (range 120-210) for five consecutive days every 14 days. Treatments were accomplished by using outpatient infusion devices. Fifteen patients